Model Answer

Recent advances in CRISPR technology have expanded the scope of gene editing beyond permanent DNA modification to include epigenetic editing. Epigenetics refers to heritable changes in gene expression that do not involve alterations in the DNA sequence. One of the most important epigenetic mechanisms is gene silencing, where chemical tags such as methyl groups attach to DNA or histone proteins, preventing the transcription machinery from accessing specific genes.

Role of epigenetic gene silencing in human diseases: Epigenetic gene silencing plays a critical role in normal development, cell differentiation, and maintenance of cellular identity. However, aberrant silencing of genes is implicated in several diseases. In cancers, tumour suppressor genes may be switched off due to abnormal DNA methylation. In genetic blood disorders such as sickle cell disease (SCD), silencing of the foetal haemoglobin (HbF) gene after birth results in the dominance of defective adult haemoglobin, leading to anaemia, pain crises, and organ damage.

Traditionally, CRISPR-Cas9–based therapies attempt to correct disease by cutting DNA to remove or modify faulty genes. While effective, this approach carries risks such as off-target mutations, chromosomal rearrangements, and long-term safety concerns.

Non–DNA-cutting CRISPR and safer gene therapy: The recent breakthrough demonstrates that CRISPR can be used to remove epigenetic methyl tags without cutting the DNA strand. By doing so, silenced genes can be reactivated in a controlled and reversible manner. In the context of sickle cell disease, reactivating the foetal haemoglobin gene allows red blood cells to function normally, significantly reducing disease severity without altering the underlying DNA sequence.

This approach offers several advantages:

1. Enhanced safety: Avoids double-strand DNA breaks, reducing unintended mutations.
2. Precision: Targets specific epigenetic markers responsible for gene silencing.
3. Reversibility: Epigenetic changes are potentially reversible, unlike permanent genetic edits.
4. Ethical acceptability: Lower risk of germline transmission and irreversible genetic changes makes it ethically preferable.

Ethical and policy dimensions From an ethical standpoint, epigenetic CRISPR aligns better with principles of non-maleficence and precaution. It addresses concerns related to long-term genetic consequences, especially in heritable diseases. However, issues of accessibility, cost, regulatory oversight, and equitable distribution remain critical, particularly for developing countries.

Conclusion Non–DNA-cutting CRISPR technologies mark a paradigm shift from gene correction to gene regulation. By harnessing epigenetic mechanisms, they promise safer, more precise, and ethically sound therapies for complex genetic disorders like sickle cell disease. As the technology matures, robust regulation and inclusive health policies will be essential to ensure its responsible application for public good.